¡Ya estamos en ! Descubre más

Arcturus Therapeutics

ARCT

Capitalización de mercado USD 294 M

10.34 USD

-0.93

8.25%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

1 día

-8.25%

5 días

-24.19%

1 mes

-33.72%

3 meses

67.31%

6 meses

16.97%

En lo que va del año

65.44%

1 año

-52.42%

5 años

-77.37%

10 años

-37.94%

Acerca de: Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

Empleados: 111

Atención médica Biotecnología

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 23.5%

Neutral 76.5%

Negativo 0%

Zacks Investment Research

4 RNA Therapeutics Stocks Leading the Next Wave of Innovation

RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.

4 RNA Therapeutics Stocks Leading the Next Wave of Innovation

Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform

Arcturus Therapeutics NASDAQ: ARCT presented preliminary Phase II data for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase, or OTC, deficiency, while outlining plans to introduce a next-generation delivery platform into the program.

Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform

Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript

Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript

Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript

Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced encouraging interim Phase 2 results from ARCT-810 in ornithine transcarbamylase (OTC) deficiency and introduced LUNAR 2.0™, the Company's next-generation mRNA delivery platform, and additional liver pipeline programs. “The ARCT-810 Phase 2 interim results validate Arcturus' m.

Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform

Arcturus Therapeutics: A Speculative Buy For Their OTC Deficiency Program

Arcturus Therapeutics is advancing mRNA-based therapies, with ARCT-810 for OTC deficiency as a near-term catalyst and ARCT-032 for cystic fibrosis in phase 2. ARCT-810 has shown promising phase 2 interim data, normalizing glutamine and ammonia levels, and is designated Orphan Drug, Fast Track, and Rare Pediatric Disease by the FDA. The upcoming Sep. 23 presentation on ARCT-810 could be stock-moving, but small trial sizes mean results should be viewed as hypothesis-generating.

Arcturus Therapeutics: A Speculative Buy For Their OTC Deficiency Program

Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will host a virtual presentation on Wednesday, September 23, 2026, at 4:30 p.m. ET. The presentation will provide an overview of the ARCT-810 Phase 2 clinical program for Ornithine transcarbamylase (OTC) deficiency and Arcturus' mRNA liver therapeutics pl.

Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform

Arcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Arcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Arcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Arcturus Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference (Boston) | Fireside Chat September 8, 2026 (2:15 p.m. ET) Citi's 2026 Biopharma Back to School Conference (New York) | Fireside Chat September 9.

Arcturus Therapeutics to Participate in Upcoming Investor Conferences

Zacks Investment Research

Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?

After reaching an important support level, Arcturus Therapeutics Holdings Inc. (ARCT) could be a good stock pick from a technical perspective. ARCT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?

Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline

Arcturus Therapeutics NASDAQ: ARCT is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is intended to help support therapeutic development, President and CEO Joseph Payne said during a Canaccord discussion.

Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™